Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Cescon

Showing results (11-20 of 133) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?David W Cescon, Kevin Kalinsky, Angela M DeMichele
Breast Cancer Research and Treatment|November 3, 2021
Breast cancer immune microenvironment: from pre-clinical models to clinical therapiesBrooke E Wilson, Chiara Gorrini, David W Cescon
Cancer Cell|January 14, 2015
Breaking up is hard to do: PI3K isoforms on the reboundDavid W Cescon, Chiara Gorrini, Tak W Mak
Current Cancer Drug Targets|March 18, 2022
Current Treatment and Future Trends of Immunotherapy in Breast CancerMitchell J Elliott, Brooke Wilson, David W Cescon
Cancer Drug Resistance (Alhambra, Calif.)|September 30, 2022
Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancerSasha C Main, David W Cescon, Scott V Bratman
Clinical and Translational Medicine|January 24, 2024
Seize the engine: Emerging cell cycle targets in breast cancerJesús Fuentes-Antrás, Philippe L Bedard, David W Cescon
Frontiers in Oncology|August 29, 2022
Patient-derived cancer models: Valuable platforms for anticancer drug testingSofia Genta, Bryan Coburn, David W Cescon, et al.
Breast Cancer Research and Treatment|October 8, 2021
Novel classes of immunotherapy for breast cancerAlberto Hernando-Calvo, David W Cescon, Philippe L Bedard
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2015
APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activationDavid W Cescon, Benjamin Haibe-Kains, Tak W Mak
European Journal of Cancer (Oxford, England : 1990)|March 30, 2017
Capecitabine in early breast cancer: A meta-analysis of randomised controlled trialsAkina Natori, Josee-Lyne Ethier, Eitan Amir, et al.
Pageof 14

Showing results (11-20 of 133) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?David W Cescon, Kevin Kalinsky, Angela M DeMichele
Breast Cancer Research and Treatment|November 3, 2021
Breast cancer immune microenvironment: from pre-clinical models to clinical therapiesBrooke E Wilson, Chiara Gorrini, David W Cescon
Cancer Cell|January 14, 2015
Breaking up is hard to do: PI3K isoforms on the reboundDavid W Cescon, Chiara Gorrini, Tak W Mak
Current Cancer Drug Targets|March 18, 2022
Current Treatment and Future Trends of Immunotherapy in Breast CancerMitchell J Elliott, Brooke Wilson, David W Cescon
Cancer Drug Resistance (Alhambra, Calif.)|September 30, 2022
Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancerSasha C Main, David W Cescon, Scott V Bratman
Clinical and Translational Medicine|January 24, 2024
Seize the engine: Emerging cell cycle targets in breast cancerJesús Fuentes-Antrás, Philippe L Bedard, David W Cescon
Frontiers in Oncology|August 29, 2022
Patient-derived cancer models: Valuable platforms for anticancer drug testingSofia Genta, Bryan Coburn, David W Cescon, et al.
Breast Cancer Research and Treatment|October 8, 2021
Novel classes of immunotherapy for breast cancerAlberto Hernando-Calvo, David W Cescon, Philippe L Bedard
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2015
APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activationDavid W Cescon, Benjamin Haibe-Kains, Tak W Mak
European Journal of Cancer (Oxford, England : 1990)|March 30, 2017
Capecitabine in early breast cancer: A meta-analysis of randomised controlled trialsAkina Natori, Josee-Lyne Ethier, Eitan Amir, et al.
Pageof 14